European Organisation for Research and Treatment of Cancer

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 19 Nov 2015
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

17,500€

Financial year: Jan 2014 - Jan 2015

Lobbyists (Full time equivalent)

1 Fte (4)

Lobbyists with EP accreditation

0

High-level Commission meetings

8

Lobbying Costs over the years

  • Info

    European Organisation for Research and Treatment of Cancer   (EORTC)

    EU Transparency Register

    70539554035-46 First registered on 20 Aug 2010

    Goals / Remit

    Created in 1962, the European Organisation for Research and Treatment of Cancer (EORTC) is a non-profit international cancer research organisation under Belgian Law. The EORTC is recognised as scientific research institution and as non-profit clinical trial sponsor by the Belgian State. The EORTC mission is to improve the standard of cancer treatment in Europe through the development of innovative new drugs and to test more effective therapeutic strategies using commercially available drugs, surgery, or radiotherapy. The EORTC has the aim to facilitate the passage of experimental discoveries into state-of-the-art treatment by keeping to a minimum the time lapse between the discovery of new anti-cancer agents and the implementation of their therapeutic benefit for patients with cancer. This is accomplished mainly by conducting international large, multicentre, prospective, randomised, phase III clinical trials.

    EORTC clinical research trials are conducted in a network of over 300 participating institutions located in 32 countries in which more than 2,900 clinicians and scientists collaborate on a voluntary basis. More than 6,000 cancer patients are entered into EORTC multidisciplinary trials each year. Some 35 EORTC trials are permanently open to patient entry. The activities of the EORTC are peer reviewed by the US National Cancer Institute. All EORTC protocols are written and conducted in accordance with international standards for ethics: the declaration of Helsinki, Good Clinical Practice guidelines approved by the International Conference on Harmonization.

    Independent clinical research is the only way to guarantee an objective evaluation and to establish optimal therapeutic strategies on a multidisciplinary base. However, there is no clinical research possible without collaboration with the industry because of the need for access to innovative new drugs and funding, etc. In order to preserve EORTC independence, EORTC studies must comply with the following basic requirements 1) Clinical study protocol must undergo EORTC pee-review procedures. Input of the academics in the design and the control arm. 2) The clinical study database must be under the full control of EORTC 3) Study primary endpoints must be analysed by independent statistician and reviewed by an Independent Data Monitoring Committee 4) Study results must be published in scientific journal 5) the study bio-samples must be under the custodianship of EORTC.

    Located in Brussels, the EORTC Headquarters is a unique facility in Europe. It provides scientific, legal, logistic and administrative support to the clinical and translational research activities of the EORTC cooperative groups (protocol development, data management, statistical analysis, new drugs development, translational research, physical and virtual biobanking, advanced imaging, quality of life, regulatory and ethical affairs management, training, Pharmacovigilance and Quality Assurance). The EORTC Headquarters staff is constituted by 180 highly experienced and trained professionals. Since 1991, the EORTC Fellowship Program has allowed more than 100 medical doctors, statisticians and health scientists from all over the world to do research project at the EORTC. The EORTC is offering a wide range of training for clinical research professionals ranging from GCP to clinical research methodology.

    Main EU files targeted

    - REGULATION (EU) No 536/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC.
    - Data Protection Regulation.
    - Regulation of the European Parliament and of the Council on in vitro diagnostic medical devices.

    Address

    Head Office
    avenue Mounier, 83
    Brussels 1200
    BELGIUM
  • People

    Total lobbyists declared

    4

    Employment timeLobbyists
    25%4

    Lobbyists (Full time equivalent)

    1

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Mr Stephane Lejeune (EU Programme Coordinator)

    Person with legal responsibility

    Mr Denis Lacombe (Director General)

  • Categories

    Category

    III - Non-governmental organisations

    Subcategory

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    European CanCer Organisation
    European Forum for Good Clinical Practice
    European Platform for Patients' Organisations, Science and Industry
    European Alliance for Personnalised Medicine
    European Association for NeuroOncology
    European Association of Urology
    European School of Oncology
    European Association of Urology
    American Association for Cancer Research
    European Society for Therapeutic Radiology and Oncology
    European Society for Medical Oncology
    American Society for Therapeutic Radiology and Oncology
    International Society of Geriatric Oncology
    International Society of Pediatric Oncology
    International Union Against Cancer
    International Network for Cancer Research and Treatment
    Organisation of European Cancer Institutes
    European Oncology Nursing Society

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2014 - Jan 2015

    Lobbying costs for closed financial year

    17,500€

    EU grant income for closed financial year

    435,018 € (Source: FP7)

    Other financial info

    The EORTC is funded through several sources including the EORTC Charitable Trust providing a core grant which is mainly supported by numerous national cancer leagues.

    Since 1972, the US National Cancer Institute (NCI) has provided support to EORTC Headquarters, and with this support a close scientific collaboration has been maintained to promote transatlantic research projects.

    Core grants from the Fonds Cancer, FOCA (BE) provide support for the EORTC Headquarters staff. EORTC Headquarters also receives grants allocated by BELSPO (the Belgian Federal Science Policy Office) and by the Belgian National Lottery.

    Funding for the Fellowship Programme is provided by the EORTC Charitable Trust, Fonds Cancer, FOCA (BE), the Koningin Wilhelmina Fund, KWF (NL), and several leagues including La Ligue Nationale contre le Cancer (FR) and the Vlaamse Liga tegen Kanker, VLK (BE).

    In addition, grants for EORTC research projects are received from the European Commission underthe 7th Framework Programmes.

    Clinical studies evaluating new drugs for potential registration or testing innovative therapeutic agents, including some educational projects, are conducted in cooperation with pharmaceutical industry partners in strict compliance with EORTC criteria for independence. Pharmaceutical industry sponsorship is also provided in the form of “unrestricted grants” for EORTC conferences.

    The finances of the EORTC include all accounts from the EORTC Headquarters as well as all EORTC Groups and Task Forces. These accounts are consolidated as required under Belgian Law. The EORTC accounts are audited by Ernst & Young.

  • EU Structures

    Groups (European Commission)

    EU Expert Group on Cancer Control

    ACC

    None

    Groups (European Parliament)

    None

    Communication activities

    Participation in workshops and conference. Position statement in collaboration with stakeholders groups such European Alliance for Personalised Medicine.

    Other activities

    - Revision of the Clinical Trials Directive 2001/20/EC
    - Support to international investigator-driven clinical trials
    - Human biological material for use in research
    - Data protection

    Keywords: Health, cancer, clinical research, medicine, drugs, surgery, radiotherapy, chemotherapy, imaging, laboratory, patient, pharmacovigilance, quality insurance, biostatistics, biobank, regulatory, insurances, quality of life, funding, new generation sequencing, molecular screening platform, health economic, Health technology assessment, survivorship, adaptive licensing.

  • Meetings

    Meetings

    8 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

Download this datacard